Loading clinical trials...

Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors | Clinical Trials | Clareo Health

COMPLETEDNA

Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors

Effects of Training and Detraining on Body Composition and Inflammatory, Oxidative and Lipid Profiles of Postmenopausal Breast Cancer Survivors Undergoing Tamoxifen Treatment

NCT04479098•Federal University of Uberlandia

View on ClinicalTrials.gov

Summary

The present study aimed to verify the effects of resistance exercise training and successive detraining on body composition, lipid profile, muscle strength, oxidative stress, and inflammatory markers of postmenopausal breast cancer survivors undergoing tamoxifen treatment.

Detailed Description

The present study aimed to verify the effects of 12 weeks of resistance exercise training and successive 12 weeks of detraining on body composition (Body Mass, Body Mass Index, Fat Mass, and Fat-Free Mass), lipid profile (Triglycerides, Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol), muscle strength (1RM test), oxidative stress (Thiobarbituric acid reactive substances,Non-Protein Thiols, Catalase activity, and Superoxide Dismutase), and inflammatory markers (Interferon γ, Tumor Necrosis Factor α, interleukin 6 , Adiponectin, and Interleukin 4) of postmenopausal breast cancer survivors undergoing tamoxifen treatment.

Eligibility

Age

40 - 65 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1\) age between 40 and 65 years; 2) stage 0-IIIA Breast Cancer; 3) submission to axillary lymphadenectomy); 4) completion of chemotherapy and radiation therapy at least 6 months before the study; 5) lack of participation in supervised physical exercise programs in the six months before the beginning of the research; 6) absence of a problem and/or musculoskeletal limitation that would prevent the performance of the proposed exercises; 7) release by a medical professional to participate in the physical training program; 8) residency in Uberlândia

Exclusion Criteria

•missing more than 20% of the exercise sessions; unable to perform the proposed training protocols; change in drug therapy during the intervention.

Locations (1)

Guilherme Morais Puga

Uberlândia, Minas Gerais, Brazil

Key Dates

Start Date

July 1, 2016

Primary Completion Date

July 31, 2017

Completion Date

June 30, 2018

Last Updated

July 21, 2020

Enrollment

ACTUAL participants

Conditions

Breast Neoplasm Female

Interventions

Resistance exercise training

OTHER

Exercise detraining

OTHER

A Novel Approach in the Evaluation of Breast Masses With Doppler US

NCT07465523

Breast Neoplasm FemaleBenign Breast Neoplasm+2 more

View study

RECRUITINGPHASE4

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

NCT03096418

Breast Neoplasm Female

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors

Inclusion Criteria

Exclusion Criteria

A Novel Approach in the Evaluation of Breast Masses With Doppler US

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

SBRT in Early Breast Cancer in Elderly Women

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer

mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public